axitinib,sorafenib,everolimus,tivozanib,cabozantinib,atezolizumab,ctx130,nivolumab,ipilimumab,Telaglenastat
bayer,novartis,bms,pfizer,crispr therapeutics ag,aveo oncology,roche,Calithera Biosciences
['nivolumab', 'nct04438083', 'thank you', 'sorafenib', 'tivo-3', 'everolimus', 'pdigree', 'rcc,(-irccs),(-srcc),(-urcc)', 'cabozantinib', 'axitinib', 'kidney cancer', 'contact-03', 'check,mate,025', 'ipilimumab', 'cobalt,rcc', 'nivo', 'tivozanib']
thank you md, mhs for the great presentation of treatment for recurrent metastatic disease, beyond second linesystemic treatment for recurrent metastatic disease, beyond second line #ascogu23 
Medical Oncologist at Centro Oncológico Integral, Hospital Ángeles Puebla. Cancer treatment must be personalized to the individual needs of the patient.